Multiple blood parameters may serve as a warning to immunochemotherapy-related interstitial lung disease in B-cell lymphoma

BACKGROUND The main aim of this study was to determine some simple but meaningful parameters that indicate immunochemotherapy-related interstitial lung disease (ILD) early in B-cell lymphoma and provide direction hematologists. METHODS clinical laboratory characteristics, the treatments outcomes 21 patients with ILD who underwent rituximab (RTX) -based immunochemotherapy were collected retrospectively analyzed. RESULTS More cycles higher cumulative doses RTX doxorubicin hydrochloride liposome conferred a high risk ILD. Compared baseline, had significantly lower white blood cell count (WBC), absolute lymphocyte (ALC), albumin level (4.95×109 vs. 6.32×109, 0.71×109 1.61×109, 34.1 40.4 g/L; P<0.05), C-reactive protein (CRP), alpha-hydroxybutyrate dehydrogenase (?-HBDH), lactate (LDH) (15.36 7.00 mg/L, 293.0 163.1 U/L, 361.8 231.1 U/L; P<0.05) levels at onset. Further, positive correlation found between glucocorticosteroid intervention good prognostication In addition, an analysis prognoses 2 cases pneumocystis pneumonia (PCP) infection indicated after 3 treatment, patients, especially unfit or those have received glucocorticoid may need receive trimethoprim/sulfamethoxazole (TMP/SMX) prevent PCP. CONCLUSIONS There relationship variations occurrence which might serve as warning for